|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Department of Plasma Proteins, CLB, Amsterdam;
Laboratory for Experimental and Clinical Immunology, Academic Medical
Center, University of Amsterdam, Amsterdam; Emma Children's Hospital
AMC, Amsterdam; and Department of Pharmaceutics, Utrecht Institute for
Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The
Netherlands.
A well-known complication of factor VIII replacement therapy
in patients with hemophilia A is the development of inhibitory antibodies. Several studies have demonstrated the presence of a binding
site for factor VIII inhibitors in the A3 domain. Six different human
monoclonal single-chain variable domain antibody fragments (scFv)
directed toward the A3-C1 domains of factor VIII have been isolated,
using phage display technology. Sequence analysis revealed that the
VH domains of 2 scFv were encoded by germline gene segments
from the VH1 gene family and 4 by germline gene segments
belonging to the VH3 gene family. Epitope mapping of the
scFv was performed, using a series of hybrid factor VIII/factor V light
chain fragments. This analysis revealed that 5 of 6 scFv were directed
against a region encompassing amino acid sequence Q1778-D1840
in the A3 domain, a previously identified binding site for factor VIII
inhibitors. Only 2 of 5 scFv directed against amino acid sequence
Q1778-D1840 inhibited the procoagulant activity of factor VIII. Our
results define the properties of human antibodies directed against
region Q1778-D1840 in the A3 domain. Binding of one, noninhibitory scFv
was independent of the region Q1778-D1840, suggesting the presence of
an additional binding site for anti-factor VIII antibodies in the
A3-C1 domains of factor VIII.
(Blood. 2001;97:966-972) Hemophilia A is an X-linked bleeding disorder that
is associated with a functional absence of factor VIII. Upon initiation of factor VIII replacement therapy, approximately 25% of patients with
severe hemophilia A develop antibodies that neutralize the procoagulant
activity of factor VIII.1 On the basis of internal sequence homology, factor VIII can be defined by the domain structure A1-a1-A2-a2-B-a3-A3-C1-C2.2,3
The majority of factor VIII inhibitors is directed toward epitopes
within the A2, C2, and A3-C1 domains of factor VIII.4
Within the A2 domain, the region R484-I508 has been identified as a
major binding site for factor VIII inhibitors.5 In the C2
domain, amino acid residues E2181-V2243 and V2248-S2312 constitute
binding sites for factor VIII inhibitors.6,7
The presence of an inhibitor binding site in the A3-C1 domains has been
suggested by inhibitor neutralization experiments, using factor VIII
light chain (a3-A3-C1-C2 domains) and isolated C2
domain.4,6 Epitope mapping with the use of in vitro
synthesized factor VIII fragments defined the epitope in the A3 domain
to amino acid residues Q1778-M1823.8 Furthermore, a
synthetic peptide corresponding to residues K1804-V1819 competed for
binding of factor VIII inhibitors to the light chain.9
This region harbors amino acid residues E1811-K1818, which comprise a
binding site for factor IXa.10 It was demonstrated that
anti-A3 inhibitor immunoglobulin G (IgG) prevents factor IXa from
binding to the factor VIII light chain.8,9 Recently, a
region involved in the binding of factor VIII inhibitors has been
localized to the acidic region a3, adjacent to the A3
domain.11 Replacement of the a3 region,
comprising amino acid residues E1649-R1689 of human factor VIII, for
the corresponding porcine sequence yielded a functional factor VIII
molecule that was less antigenic to factor VIII inhibitors. The binding
site for von Willebrand factor has been localized to the a3
region, which is released following cleavage at position R1689 by
thrombin.12-14 Inhibitory antibodies directed toward this
region may prevent activation of factor VIII when complexed to von
Willebrand factor.
Assembly of antibody genes occurs by random rearrangement of different
gene segments.15 The primary variable region of the heavy
chain (VH) is generated by random recombination of variable (VH), diversity (D), and joining (JH) gene
segments that are present in multiple copies in the germline DNA. At
the moment, 123 different VH gene segments have been
identified, which can be classified into 7 different families
(VH1 to VH7), based on nucleotide sequence homology.16,17 Two independent studies determined that
only 3917 or 5116 of the VH gene
segments are functional, whereas the remaining genes are mainly
pseudogenes that are nonfunctional because of point mutations or
truncations. For assembly of the primary variable light chain region
(VL), a VL gene segment, either of Recently, we have used phage display technology to isolate anti-A2 and
anti-C2 antibodies from the immunoglobulin repertoires of patients with
an inhibitor to factor VIII.18,19 Analysis of human
anti-C2 antibodies revealed that their immunoglobulin heavy-chain
variable (VH) domains were exclusively encoded by VH gene segments derived from the VH1 gene
family. These findings suggest that only a subset of VH
gene segments is used to generate human anti-C2 antibodies. Molecular
analysis of anti-A2 antibodies revealed that a single VH
domain encoded by gene segment DP-10 (1-69) of the
VH1 gene family is involved in assembly of a human antibody
that binds to region R484-I508 in the A2 domain. Furthermore, an
additional human antibody composed of a VH domain encoded
by gene segment DP-47 (3-23) of the VH3 gene family, bound
to residues D712-A736 in the acidic region a2, a previously
unidentified binding site for anti-factor VIII
antibodies.19
In the present study, phage display technology was used to further
define the molecular characteristics of human antibodies reactive with
the A3-C1 domains of factor VIII. The majority of the isolated
antibodies was directed toward amino acid sequence Q1778-D1840 of
factor VIII. Our results indicate that different residues in this
region are involved in the binding of the various scFv. One of the
isolated scFv did not react with this region, suggesting the presence
of an additional binding site for anti-factor VIII antibodies in the
A3-C1 domains of factor VIII.
Materials
Factor VIII assays
Construction of hybrid FVIII/FV light-chain hybrids A series of hybrid factor VIII/factor V light-chain expression vectors were constructed by overlap extension mutagenesis, using vector pCLB-GP67-80K,20 encoding the light chain of factor VIII (amino acid residues E1649-Y2332), and factor V complementary DNA (cDNA) as templates. Three hybrid constructs were made in which amino acids residues R1803-K1818 (HV1803-1818), Q1778-H1821 (HV1778-1821), or K1804-D1840 (HV1804-1840) were replaced for the corresponding sequence of factor V (Figure 2A). Expression of metabolically labeled factor VIII light-chain hybrids in insect cells was performed as described.20Phage display library construction and selection In this study, peripheral blood mononuclear cells from a previously described inhibitor patient8 served as the source of RNA for the construction of a phage display library essentially as described previously.18 The patient's IgG4-specific VH gene repertoire was amplified, using appropriate VH gene family-based VH back primers and an IgG4 constant region primer as described.18 Subsequently, each VH repertoire was cloned separately in the phagemid pHEN-1-VLrep,25 which contained an immunoglobulin light-chain variable (VL) gene repertoire of nonimmune origin.Phage were selected for binding to the factor VIII light chain essentially as described previously.18 In this study, microtiter wells (Dynatech, Plockingen, Germany) were immobilized with antibody CLB-CAg 117, which is directed toward the C2 domain of factor VIII.8 Wells were blocked with Tris-buffered saline (TBS; 150 mM NaCl, 50 mM Tris, pH 7.4), 3% (wt/vol) human serum albumin (HSA) for 2 hours at 37°C. Phage in TBS, 3% HSA, and 0.5% (vol/vol) Tween-20 were preincubated for 2 hours at room temperature in CLB-CAg 117-coated wells to reduce nonspecific binding. Subsequently, CLB-CAg 117-coated wells were incubated for 2 hours at 37°C with 25 nM plasma-derived factor VIII light chain in 1 M NaCl, 50 mM Tris, pH 7.4, 2% HSA, and blocked with HSA as outlined above. For specific binding of phage directed toward factor VIII light chain, these wells were incubated for 2 hours at room temperature with nonbound phage transferred from the preincubations. After washing with TBS/0.1% (vol/vol), Tween-20, and TBS (both 20 times), bound phage were eluted with 100 mM triethylamine and rescued, using Escherichia coli TG1.26 The selection procedure was performed for a total of 3 rounds. Screening and sequencing of selected clones After the third round of selection, phage derived from 15 single infected colonies were tested for reactivity with factor VIII. The domain specificity was evaluated by testing reactivity of phage with factor VIII light chain and recombinant C2 fragment immobilized via antibody CLB-CAg 117.18 Bound phage was detected by anti-M13 antibody peroxidase conjugate (Pharmacia-LKB, Woerden, The Netherlands).27 Sequences encoding the VH and VL domains were determined using the BigDye Terminator sequencing kit on an Applied Biosystems 377XL automated DNA sequencer (Foster City, CA). Genes were aligned with a database of germline V genes as compiled in the V-BASE sequence directory.28Characterization of scFv For production of single-chain variable domain antibody fragments (scFv), V genes were subcloned into the vector pUC119-Sfi/Not-His6,29 which introduces a carboxy-terminal 6 × histidine tag in the scFv. Expression and purification of scFv was performed as described previously.30 Purified scFv were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and protein concentrations were measured spectrophotometrically at A280. Reactivity of scFv with hybrid factor VIII/factor V light-chain fragments and C2 domain was evaluated by immunoprecipitation analysis. Immunoprecipitation of metabolically labeled factor VIII fragments by scFv/Ni-NTA agarose (Qiagen, Hilden, Germany) complexes was performed as described previously.18Reactivity of scFv with the region comprising amino acid residues E1649-R1689 of the factor VIII light chain was determined as follows. Factor VIII light chain and thrombin-cleaved factor VIII light chain (0.4 nM) were captured on antibody CLB-CAg 117-coated wells as described above. Wells were incubated with scFv (0-100 nM) in TBS/2% HSA and 0.1% (vol/vol) Tween-20 for 2 hours at room temperature. Bound scFv were detected using peroxidase-labeled antibody 9E10. Antibody 9E10 is directed toward the scFv's carboxy-terminal myc-tag. Surface plasmon resonance The kinetics of the interaction between scFv and factor VIII light chain were determined by surface plasmon resonance, using a BIAcore2000 biosensor system (Biacore AB, Uppsala, Sweden). ScFv were covalently coupled at the indicated densities to the dextran surface of an activated CM5-sensor chip, using the amine-coupling kit according to the manufacturer's instructions (Biacore AB). A control flow-channel was routinely activated and blocked in the absence of protein. Binding to coated channels was corrected for binding to noncoated channels (< 5% of binding to coated channels). Binding (association) of ligand was assessed in 200 mM NaCl, 2 mM CaCl2, 0.05% (v/v) Tween 20, and 20 mM HEPES, pH 7.4 at 25°C for 2 minutes at a flow rate of 20 µL/min. Dissociation was allowed for 2 minutes in the same buffer flow. Association (kon) and dissociation (koff) rate constants of data sets were determined using the BIAevaluation software. Binding data were corrected for bulk refractive index changes and fitted according to a one-site model. Equilibrium dissociation constants (Kd) were calculated as koff/kon.
Characterization of anti-factor VIII antibodies in patient's plasma Previously, we have shown that amino acid residues Q1778-M1823 in the A3 domain constitute a binding site for factor VIII inhibitors. This initial characterization of factor VIII inhibitors was performed, using a plasma sample with an inhibitor titer of 40 BU/mL of a patient with severe hemophilia A.8 Following treatment of the same patient with factor VIII inhibitor bypassing agent (FEIBA), the inhibitor titer increased to 200 BU/mL. In this study, we first evaluated the domain specificity of anti-factor VIII antibodies in the latter plasma sample. Immunoprecipitation analysis showed reactivity of antibodies with the factor VIII light chain as well as the C2 domain (Figure 1; lanes 5 and 6). To determine to what extent anti-C2 domain antibodies contribute to the inhibitor titer, an inhibitor neutralization assay was performed. Addition of factor VIII light chain completely neutralized factor VIII inhibitory activity, whereas 30% neutralization was achieved on addition of C2 domain (data not shown). This suggests that the majority of factor VIII inhibitory antibodies is directed toward a region located outside the C2 domain. The patient's anti-factor VIII antibodies consisted predominantly of subclass IgG4 (data not shown). Therefore, a subclass-specific oligonucleotide primer was used to selectively amplify the patient's IgG4-specific VH gene repertoire. Recombination of the IgG4-enriched VH gene repertoire with a nonimmune VL gene repertoire in pHEN-1-VLrep yielded a phage library of 1.9 × 107 clones.
Isolation and sequence analysis of antibodies directed toward the A3 domain of factor VIII After 3 rounds of selection, the domain specificity of phage derived from 15 single clones was analyzed. All analyzed clones reacted with the factor VIII light chain but not with the C2 domain (data not shown). Sequence analysis of these clones revealed the presence of 6 different VH genes. The VH genes of clones KM37 and KM41 were derived from germline gene segments DP-14 and DP-15, respectively (Table 1), both belonging to the VH1 gene family. The remaining 4 VH genes were derived from VH3 family gene segments; 2 from gene segment DP-49 (KM33 and KM38) and 2 from DP-77 (KM35 and KM36). The VH genes harbor 21 to 31 nucleotide substitutions compared to their nonmutated germline gene segments. This resulted in 9 to 18 amino acid replacements in the encoded VH domains. Deduced amino acid sequences of the VH domains are shown in Table 2. Both VH genes of clones KM35 and KM36, which are highly homologous, used gene segment JH3b for VDJ rearrangement. JH4b was identified as the most homologous JH gene segment in clones KM38 and KM41 and JH6 in KM37. In the VH domain of KM33, no particular JH gene segment could be identified, possibly as a consequence of extensive somatic hypermutation and/or N-addition and deletion at the junction between D and JH gene segments. The presence of a particular D gene segment could only be established in clone KM37 in which gene segment D3-3 was rearranged. VL domains of clones KM35 and KM36 were encoded by germline gene segment DPL16, a member of the V 3 gene family. The
other 4 VH domains paired with VL domains
derived from different gene segments belonging to the V I
and VIII gene families (Table 1).
Biochemical characterization of A3-C1-specific scFv For the expression of scFv, the different VH and VL genes were subcloned in the expression vector pUC119-Sfi/Not-His6.29 To define the domain specificity of the isolated scFv, their reactivity was evaluated by immunoprecipitation analysis, using metabolically labeled factor VIII light chain and C2 domain. Expression of the factor VIII fragments was monitored by binding of scFv EL-14 (Figure 2B; lane 9), a previously described anti-C2 domain scFv.18 All scFv, except for a control scFv that was directed toward the A2 domain (Figure 2B; lane 8), reacted with the factor VIII light chain. None of the isolated scFv bound to the C2 domain, indicating that all 6 patient-derived scFv are directed toward an epitope in the A3-C1 domains (Figure 2B).
The interaction of isolated scFv with the factor VIII light chain was explored in more detail by mutagenesis in the previously described binding site for anti-A3 antibodies.8,9 Three factor VIII/factor V light-chain hybrids were constructed that contained factor V replacements in the regions R1803-K1818 (HV1803-1818), Q1778-H1821 (HV1778-1821) or K1804-D1840 (HV1804-1840) (Figure 2A). Inspection of a 3-dimensional model of the triplicated A domains of factor VIII revealed that the majority of the amino acids within amino acid sequence Q1778-D1840 are located at the surface of the A3 domain.32,33 First, reactivity of antibody CLB-CAg A, whose binding site has been localized to residues K1804-K1818,10 with the different hybrids was evaluated. As expected, CLB-CAg A did not recognize any of the hybrid factor VIII/factor V fragments (Figure 2B, lane 10). In agreement with previous data, these findings indicate that the epitope of CLB-CAg A is localized within region R1803-K1818. Similar to CLB-CAg A, one of the isolated scFv, KM41, did not react with the different hybrid fragments, suggesting that the epitope of scFv KM41 is also contained within amino acid sequence R1803-K1818 (Figure 2B; lane 7). No reactivity of scFv KM35 and KM36 with hybrids HV1778-1821 and HV1804-1840 was observed, whereas both scFv readily react with hybrid HV1803-1818 (Figure 2B; lanes 3 and 4). This points at an essential role for factor VIII residues surrounding sequence R1803-K1818 in the binding of scFv KM35 and KM36 to the light chain of factor VIII. ScFv KM33 and KM37 reacted with hybrid HV1803-1818, whereas binding of both scFv to HV1778-1821 was reduced (Figure 2B; lanes 2 and 5). Virtually no binding of scFv KM33 and KM37 to HV1804-1840 was observed, suggesting that residues within this region are essential for binding of these scFv to the A3 domain. All tested factor VIII light-chain hybrids were bound to a similar extent by scFv KM38 (Figure 2B, lane 6). Therefore, its epitope must be located outside the region Q1778-D1840. Recently, a binding site for factor VIII inhibitors has been assigned to amino acid residues E1649-R1689 at the amino-terminus of the factor VIII light chain.11 Binding of KM38 to thrombin-cleaved factor VIII light chain was evaluated. Following thrombin cleavage at position R1689, the region E1649-R1689 is removed from the factor VIII light chain. In an enzyme-linked immunosorbent assay, scFv KM38 exhibited similar binding to factor VIII light chain and thrombin-cleaved factor VIII light chain (data not shown). These findings suggest that scFv KM38 recognizes an epitope elsewhere in the A3-C1 domains of factor VIII. The capacity of each scFv to inhibit factor VIII procoagulant activity
was evaluated in a Bethesda assay.24 Only scFv KM33 and
KM41 inhibited factor VIII activity with inhibitor titers of 97 and 63 BU/mg, respectively. The other scFv did not inhibit factor VIII
activity (titer < 5 BU/mg scFv). To determine whether the observed
Bethesda titer of each scFv corresponds with its affinity for the
factor VIII light chain, we measured the association rate constant
(kon) and dissociation rate constant
(koff) of the factor VIII light chain for the
different scFv by surface plasmon resonance. Addition of factor VIII
light chain to immobilized scFv KM41 resulted in a time-dependent
increase in mass detected on the sensor chip that reflects binding of
factor VIII light chain to immobilized scFv (Figure
3). Fitting of this part of the curve
yielded a kon of 1.8 × 105
M
A significant portion of plasmas of patients with inhibitors to
factor VIII are known to contain antibodies that bind to the A3-C1
domains.4,6 In the present study, 6 different human antibodies directed toward the A3-C1 domains were isolated from the
immunoglobulin repertoire of a single patient. Previously, we and
others have shown that the VH domains of anti-C2 antibodies are preferentially encoded by germline gene segments derived from the
VH1 gene family.18,34,35 The results of the
present study suggest that anti-A3-C1 antibodies are composed of
VH domains derived from multiple germline gene segments of
the VH1 and VH3 family. Germline gene segments
of the VH1 and VH3 family occur in,
respectively, 15% and 55% of human peripheral IgG+ B
cells.36 The individual germline gene segments DP-49
(3-30) DP-77 (3-21), and DP-14 (1-18) that encode anti-A3-C1
antibodies are present in 5% to 10% of the total immunoglobulin
repertoire.36 In contrast, germline segment DP-15 (1-8)
that has been used for assembly of scFv KM41 (Table 1) is present with
a low frequency (< 0.5%) in the immunoglobulin repertoire. These
observations suggest that, in contrast to, for example, human
anti-Rh(D) antibodies, which are almost exclusively derived from
members of the "VH3-33 superspecies" Five of 6 scFv bound to amino acid sequences contained within the region Q1778-D1840 in the A3 domain. These findings confirm that this part of the A3 domain comprises a major binding site for factor VIII inhibitors.8,9 Within amino acid sequence Q1778-D1840, an interactive site for factor IXa has been localized to amino acid residues E1811-K1818.10 Binding of factor VIII inhibitors to this site in the A3 domain interferes with binding of factor IXa.8,9 Surprisingly, only 2 of 6 scFv described in this study effectively inhibited the procoagulant activity of factor VIII. In the following paragraphs, potential explanations for the different functional properties of the isolated scFv will be discussed. Binding of the inhibitory scFv KM41 is dependent on residues R1803-K1818, which contain a binding site for factor IXa. Previously, we have shown that monoclonal antibody CLB-CAg A binds to a synthetic peptide comprising these residues.10 Replacement of residues R1803-K1818 by the corresponding sequence of factor V abolishes binding of CLB-CAg A to the factor VIII light chain (Figure 2B). CLB-CAg A interferes with binding of factor IXa to the factor VIII light chain.21 In view of the similar epitope specificity of scFv KM41 and CLB-CAg A, it is likely that scFv KM41 competes with factor IXa for binding to the factor VIII light chain. Also, scFv KM33 inhibits the procoagulant activity of factor VIII, although its epitope is located outside region R1803-K1818 (Figure 2B). Binding of scFv KM33 is primarily affected by replacements in the carboxy-terminal part of sequence Q1778-D1840. The epitope specificity of scFv KM33 is remarkably similar to that of scFv KM37, which does not inhibit factor VIII procoagulant activity. It should be noted that the VH domains of scFv KM33 and KM37 are derived from different VH gene segments, which may endow these scFv with different biochemical properties. Both scFv KM35 and KM36 do not inhibit factor VIII procoagulant activity, and binding of both scFv is dependent on residues contained within regions surrounding R1803-K1818. The VH domains of these scFv differ at only 3 amino acid positions, which may explain their similar epitope specificity. The lack of inhibition of factor VIII activity by scFv KM35 and KM36 is most likely explained by their low affinity for the factor VIII light chain in comparison to scFv KM33 and KM41 (Figure 3). Because of their lower affinity for factor VIII, scFv KM35 and KM36 may not be able to efficiently compete for binding of factor IXa to the factor VIII light chain. The epitope specificity of the noninhibitory scFv KM37 overlaps with that of the inhibitory scFv KM33 (Figure 2B). The low affinity scFv KM37, compared to that of scFv KM33, for the factor VIII light chain may explain its inability to block the procoagulant activity of factor VIII. Taken together, it seems likely that high-affinity binding of scFv to factor VIII light chain is a prerequisite for factor VIII inhibition. Inspection of the 3-dimensional homology model of the A domains of factor VIII reveals that, within region Q1778-D1840, amino acid residues Y1792-A1834 are exposed.32 The factor IXa binding site present within region R1803-K1818 is located at one site of this region, whereas regions Q1778-P1802 and V1819-D1840 are in close contact but oriented away from residues R1803-K1818.33 On the basis of the diameter of an antigen-binding site of 3.0 nm,38 region Q1778-D1840 can accommodate at least 2 separate binding sites for scFv. The first binding site may overlap with residues R1803-K1818, and antibodies directed against this site are likely to interfere with binding of factor IXa. The second binding site may be composed of residues derived from both regions Q1778-P1802 and V1819-D1840. This hypothesis is compatible with our findings on the reactivity of scFv with the hybrid factor VIII/factor V light-chain fragments. The inhibitory scFv KM41 and mAb CLB-CAg A are targeted to the factor IXa binding site present within region R1803-K1818. In contrast, binding of KM33, KM35, KM36, and KM37 to factor VIII is sensitive to replacement of amino acid sequences surrounding R1803-K1818. ScFv binding to this site may not necessarily interfere with factor VIII activity because most of these residues are not in close proximity to the factor IXa binding site at E1811-K1818. Because of the smaller size of scFv (30 kd) compared to that of complete antibodies (150 kd), we cannot exclude that a complete antibody molecule that binds to regions Q1778-P1802 and V1819-D1840 can interfere with factor VIII procoagulant activity. Also, complete antibody molecules may bind with a higher affinity to the factor VIII light chain compared to the corresponding scFv. Finally, it should be noted that the scFv described in this report contain VL domains that are derived from a nonimmune source. Phage display does not preserve the original VH-VL pairing as found in anti-A3-C1 antibodies present in patient's plasma. Potentially, both affinity and epitope specificity may be modulated by substituting the VL chain of the scFv for a different, patient-derived light chain. The epitope specificity of scFv KM38 clearly differs from that of the other scFv isolated in this study. Presumably, scFv KM38 corresponds to anti-factor VIII antibodies that recognize an additional epitope in the A3-C1 domains. ScFv KM38 is not directed against amino acid residues E1649-R1689, a recently described epitope for factor VIII inhibitors in the acidic region at the amino-terminus of the factor VIII light chain.11 Human antibodies directed against this region are often accompanied by inhibitory antibodies directed against other parts on factor VIII and are not present in plasma of all inhibitor patients. Most likely, antibodies with this specificity are not sufficiently represented in the repertoire of the patient described in this study to allow for their isolation by phage display. Competition experiments revealed that the epitope of scFv KM38 overlaps with that of antibody CLB-CAg 12, a noninhibitory mAb directed against the A3-C1 domains of factor VIII (data not shown). Only a single scFv that bound outside region Q1778-D1840 has been found in this study, suggesting that human antibodies corresponding to scFv KM38 occur with a low frequency in the immunoglobulin repertoire of inhibitor patients.
We thank C. van der Zwaan for providing factor V cDNA, P. H. N. Celie for providing purified factor VIII light chain, and G. van Stempvoort for the construction of HV1803-1818. We are also grateful to W. G. van Aken, R. C. Aalberse, and P. J. Lenting for critical reading of the manuscript.
Submitted April 14, 2000; accepted October 23, 2000.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Jan Voorberg, Department of Plasma Proteins, CLB, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands; e-mail: j_voorberg{at}clb.nl.
1.
Hoyer LW.
Haemophilia A.
N Engl J Med.
1994;330:38-47 2. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature. 1984;312:337-342[CrossRef][Medline] [Order article via Infotrieve].
3.
Lenting PJ, van Mourik JA, Mertens K.
The life cycle of coagulation factor VIII in view of its structure and function.
Blood.
1998;92:3983-3996
4.
Prescott R, Nakai H, Saenko EL, et al.
The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies.
Blood.
1997;89:3663-3671
5.
Healey JF, Lubin IM, Nakai H, et al.
Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII.
J Biol Chem.
1995;270:14505-14509
6.
Scandella D, Gilbert GE, Shima M, et al.
Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site.
Blood.
1995;86:1811-1819
7.
Healey JF, Barrow RT, Tamim HM, et al.
Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII.
Blood.
1998;92:3701-3709
8.
Fijnvandraat K, Celie PHN, Turenhout EAM, et al.
A human allo-antibody interferes with binding of factor IXa to the factor VIII light chain.
Blood.
1998;91:2347-2352
9.
Zhong D, Saenko EL, Shima M, Felch M, Scandella D.
Some human inhibitor antibodies interfere with factor VIII binding to factor IX.
Blood.
1998;92:136-142
10.
Lenting PJ, Van de Loo JWP, Donath M-JSH, van Mourik JA, Mertens K.
The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX.
J Biol Chem.
1996;271:1935-1940
11.
Barrow RT, Healey JF, Gailani D, Scandella D, Lollar P.
Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules.
Blood.
2000;95:564-568 12. Leyte A, Verbeet MP, Brodniewicz-Proba T, Van Mourik JA, Mertens K. The interaction between human blood-coagulation factor VIII and von Willebrand factor: characterization of a high-affinity binding site on factor VIII. Biochem J. 1989;257:679-683[Medline] [Order article via Infotrieve].
13.
Leyte A, van Schijndel HB, Niehrs C, et al.
Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor.
J Biol Chem.
1991;266:740-746
14.
Saenko EL, Scandella D.
The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor.
J Biol Chem.
1997;272:18007-18014 15. Tonegawa S. Somatic generation of antibody diversity. Nature. 1983;302:575-581[CrossRef][Medline] [Order article via Infotrieve]. 16. Cook GP, Tomlinson IM. The human immunoglobulin VH repertoire. Immunol Today. 1995;16:237-242[CrossRef][Medline] [Order article via Infotrieve].
17.
Matsuda F, Ishii K, Bourvagnet P, et al.
The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus.
J Exp Med.
1998;188:2151-2162
18.
van den Brink EN, Turenhout EAM, Davies J, et al.
Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes.
Blood.
2000;95:558-563
19.
van den Brink EN, Turenhout EAM, Bank CMC, et al.
Molecular analysis of human anti-factor VIII antibodies by V gene phage display identifies a new epitope in the acidic region following the A2 domain.
Blood.
2000;96:540-545
20.
Fijnvandraat K, Turenhout EAM, van den Brink EN, et al.
The missense mutation Arg593
21.
Lenting PJ, Donath M-JSH, van Mourik JA, Mertens K.
Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII.
J Biol Chem.
1994;269:7150-7155
22.
Donath M-JSH, Lenting PJ, van Mourik JA, Mertens K.
The role of cleavage of the light chain at positions Arg1689 or Arg1721 in subunit interaction and activation of human blood coagulation factor VIII.
J Biol Chem.
1995;270:3648-3655 23. Veltkamp JJ, Drion EF, Loeliger EA. Detection of the carrier state in hereditary coagulation disorders; II: Thromb Diath Haemorrh. 1968;19:403-422[Medline] [Order article via Infotrieve]. 24. Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34:869-872[Medline] [Order article via Infotrieve].
25.
Griffin HM, Ouwehand WH.
A human monoclonal antibody specific for the leucine-33 (p1A1, HPA-1a) form of platelet glycoprotein IIIa from a V gene phage display library.
Blood.
1995;86:4430-4436 26. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization: human antibodies from V-gene libraries displayed on phage. J Mol Biol. 1991;222:581-597[CrossRef][Medline] [Order article via Infotrieve]. 27. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature. 1990;348:552-554[CrossRef][Medline] [Order article via Infotrieve]. 28. Tomlinson IM, Williams SC, Ignatovitch O, Corbett SJ, Winter G. V Base Sequence Directory. Cambridge United Kingdom: MRC Centre for Protein Engineering; 1999. 29. Griffiths AD, Williams SC, Hartley O, et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 1994;13:3245-3260[Medline] [Order article via Infotrieve]. 30. Schier R, Marks JD, Wolf EJ, et al. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology. 1995;1:73-81[CrossRef][Medline] [Order article via Infotrieve]. 31. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of immunological interest. 5th ed. Bethesda, MD: US Department of Health and Human Services; 1991.
32.
Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EGD, Kemball-Cook G.
A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin.
Blood.
1997;89:2413-2421 33. Mertens K, Celie PHN, Kolkman JA, Lenting PJ. Factor VIII-factor IX interactions: molecular sites involved in enzyme-cofactor complex assembly. Thromb Haemost. 1999;82:209-217[Medline] [Order article via Infotrieve].
34.
Jacquemin MG, Desqueper BG, Benhida A, et al.
Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor.
Blood.
1998;92:496-506 35. Arai M, Imai T, Yuguchi M, Nakashima T, Kukutake K. Cloning and characterization of single chain Fv of anti-factor VIII antibody derived from a hemophilia A patient with factor VIII inhibitor [abstract]. Thromb Haemost. 1999;82:238a. 36. de Wildt RMT, Tomlinson IM, van Venrooij WJ, Winter G, Hoet RMA. Comparable heavy and light chain pairings in normal and systemic lupus erythematosus IgG+ B cells. Eur J Immunol. 2000;30:254-261[CrossRef][Medline] [Order article via Infotrieve].
37.
Chang TY, Siegel DL.
Genetic and immunological properties of phage-displayed human anti-Rh(D) antibodies: implications for Rh(D) epitope topology.
Blood.
1998;91:3066-3078
38.
Sheriff S, Silverton EW, Padlan EA, et al.
Three-dimensional structure of an antibody-antigen complex.
Proc Natl Acad Sci U S A.
1987;84:8075-8079
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  H. Meems, A. B. Meijer, D. B. Cullinan, K. Mertens, and G. E. Gilbert Factor VIII C1 domain residues Lys 2092 and Phe 2093 contribute to membrane binding and cofactor activity Blood, October 29, 2009; 114(18): 3938 - 3946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lacroix-Desmazes, A.-M. Navarrete, S. Andre, J. Bayry, S. V. Kaveri, and S. Dasgupta Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A Blood, July 15, 2008; 112(2): 240 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Bovenschen, R. C. Boertjes, G. van Stempvoort, J. Voorberg, P. J. Lenting, A. B. Meijer, and K. Mertens Low Density Lipoprotein Receptor-related Protein and Factor IXa Share Structural Requirements for Binding to the A3 Domain of Coagulation Factor VIII J. Biol. Chem., March 7, 2003; 278(11): 9370 - 9377. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
or 
origin, is combined with a JL gene segment. Lack of the D
gene segment in VL gene recombination results in a
VL repertoire that displays limited diversity compared to
the VH repertoire. As a consequence of the far greater
diversity of the VH domain, it is suggested that the heavy
chain provides the major contribution to antigen recognition and
specificity. Besides combinatorial diversity, addition and deletion of
nucleotides at the sites of V(D)J gene junction gives rise to
diversity, particularly in the third complementarity-determining region
(CDR3) of both VH and VL domains.
) control (scFv directed toward the A2 domain of factor
VIII); (lane 9)
1s
closely related
germline gene segments DP-49 (3-30/3-30.5), DP-46 (3-30.3), and DP-50
(3-33)
Cys is related to antibody formation in a patient with mild hemophilia A.
Blood.
1997;89:4371-4377